Register Login

All Posts

Poster: Monitoring FVIII in Hemophilia Patients Treated with Bypassing Therapeutics

To review the PBI poster presented at the 2025 ISTH meeting, click Effect of Mim8 and Emicizumab on Factor VIII Recovery by a Novel, Bovine Chromogenic FVIII Assay. Tara Quinton, Meghan Bruhm, Karen M. Black, Ali Sadeghi-Khomami. Precision BioLogic Inc., Dartmouth, Nova Scotia, Canada. The poster illustrates the validity of bovine reagent-based chromogenic substrate FVIII […]
read more

July 2025 Quick Question: Hemophilia Therapeutics

At the June 21–25 ISTH meeting in Washington, DC, we heard several quality presentations describing the new hemophilia treatment materials, including updated EHL concentrates plus the bypassing, rebalancing, and gene transfer therapies. In follow-up, our July 2025 Quick Question asks you to select the choice that represents the recently approved rebalancing therapies. Please make your […]
read more

Lab Assessment of FVIII Inhibitors

Click here for an open-access article describing the need for factor inhibitor assessment: Favaloro EJ, Curnow J, Pasalic L. Laboratory assessment of factor VIII inhibitors: when is it required? A perspective informed by local practice. J Clin Med. 2024;14:13. doi: 10.3390/jcm14010013. PMID: 39797095; PMCID: PMC11720995. See also our factor inhibitor discussions under the Bleeding Disorders heading.
read more